Breast Cancer | Specialty

Dr. Tripathy Discusses the MONALEESA-7 Trial in HR+ Breast Cancer

June 2nd 2019

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.

Ribociclib Improves Survival by Nearly 30% for Premenopausal Women With Advanced Breast Cancer

June 1st 2019

Ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared 46.0% for placebo and endocrine therapy in premenopausal women with HR-positive, HER2-negative advanced breast cancer.

Dr. Esteva on the Prevalence of Precision Medicine in Breast Cancer

May 30th 2019

Francisco J. Esteva, MD, PhD, director, Breast Medical Oncology, professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the prevalence of precision medicine in the treatment of patients with breast cancer.

COTA, FDA Agree to Collaborate on Breast Cancer Research

May 30th 2019

COTA, Inc., a leading precision medicine technology company, has signed a 2-year Research Collaboration Agreement with the FDA’s Information Exchange and Data Transformation program.

FDA Grants Lasofoxifene Fast Track Designation for ER+/ESR1-Mutant Metastatic Breast Cancer

May 29th 2019

The FDA has granted a fast track designation to lasofoxifene for use as a treatment of female patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who harbor ESR1 mutations.

Significance of Genetic Testing Continues to Increase in Breast Cancer

May 29th 2019

Banu Arun, MD, discusses how the role of genetic testing is evolving in breast cancer with the development of new targeted agents.

FDA Approves Alpelisib for Breast Cancer

May 24th 2019

The FDA has approved the PI3K inhibitor alpelisib (Piqray) for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

Experts Say DCIS Requires Focus on Genomics and Microenvironment

May 21st 2019

Identifying patients with DCIS who are more likely to develop invasive breast cancer remains a challenge. However, two major areas of study are the appropriate use of active surveillance and the use of biomarkers observed in the DCIS microenvironment to determine risk.

Pembrolizumab Misses OS Endpoint in Metastatic TNBC

May 21st 2019

Single-agent pembrolizumab (Keytruda) did not meet a prespecified endpoint of superior overall survival compared with chemotherapy as a second- or third-line treatment for patients with metastatic triple-negative breast cancer, missing the primary endpoint of the phase III KEYNOTE-119 trial.

Low-Fat Diet Could Reduce Risk of Death From Breast Cancer

May 16th 2019

Women who eat a balanced, low-fat diet and daily portions of vegetables, fruit, and grains have a 21% lower risk of dying from breast cancer.

CDK4/6 Inhibitors Firmly Established in HR+ Breast Cancer, OS Data Awaited

May 9th 2019

Daphne B. Stewart, MD, highlights the pivotal trials evaluating CDK4/6 inhibitors and what unanswered questions remain with this class of agents.

Axilla Management Approach Evolving in Breast Cancer

May 8th 2019

Laura Kruper, MD, MS, discusses outstanding questions within the context of the current management of the axilla.

FDA Grants Fast Track Designation to Leronlimab for Metastatic TNBC

May 8th 2019

The FDA has granted a fast track designation to the CCR5 antagonist leronlimab for use in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer.

Translating Trial Data to Treatment in Metastatic TNBC

May 6th 2019

Yuan Yuan, MD, PhD, discusses how treating physicians are optimizing novel agents for patients with metastatic triple-negative breast cancer.

Dr. Glaser on Managing Radiation-Induced AEs in Early Breast Cancer

May 2nd 2019

Scott Glaser, MD, assistant clinical professor of radiation oncology, City of Hope, discusses strategies for managing radiation-induced adverse events in patients with early-stage breast cancer.

Roswell Park Metastatic Breast Cancer Studies Focus on New Immunotherapies

April 30th 2019

Second-generation immuno-oncology studies hold great promise for breaking through the known barriers highlighted by earlier research against metastatic breast cancer.

Talazoparib Approaches EU Approval for BRCA-Mutated, HER2-Negative Breast Cancer

April 30th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use has backed approval of talazoparib (Talzenna) for adult patients with HER2-negative locally advanced or metastatic breast cancer harboring germline BRCA1/2 mutations.

Potential Evolutions in the TNBC Treatment Paradigm

April 29th 2019

Applying IMpassion130 Data to TNBC Management

April 29th 2019

I-O in TNBC: IMpassion130 Trial Design and Results

April 29th 2019